Musmar Basel, Orscelik Atakan, Salim Hamza, Musmar Fares, Adeeb Nimer, Naamani Kareem El, Essibayi Muhammed Amir, Spellicy Samantha, Abdelgadir Jihad, Dmytriw Adam A, Patel Aman B, Pereira Vitor Mendes, Cuellar-Saenz Hugo H, Guthikonda Bharat, Zomorodi Ali, Jabbour Pascal, Hasan David
Department of Neurosurgery, Duke University Hospital, Durham, NC, USA.
Department of Neurosurgery, Division of Neuroendovascular Surgery, Medical University of South Carolina, Charleston, SC, USA.
Interv Neuroradiol. 2024 Jul 25:15910199241264345. doi: 10.1177/15910199241264345.
Advancements in flow diversion technology have revolutionized the treatment of intracranial aneurysms. The pipeline embolization device (PED) and the flow redirection endoluminal device (FRED) have emerged as prominent tools in this field. This study aims to compare the safety and efficacy profiles of PED and FRED in the treatment of intracranial aneurysms.
Following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted across PubMed, Web of Science, and Scopus databases. Studies comparing PED and FRED were included and data extraction focused on study characteristics, patient demographics, and clinical and radiological outcomes. Primary outcomes were favorable outcomes, described as modified Rankin scale (mRS) 0-2 score, and complete/near-complete occlusion, while secondary outcomes included retreatment rate and thromboembolic and hemorrhagic complications.
Five studies, comprising 1238 patients, were included. No significant differences were found between PED and FRED in terms of complete occlusion at 6 months and 1 year, complete/near-complete occlusion at the last follow up, retreatment rates, and thromboembolic, in-stent thrombosis and hemorrhagic complications. However, FRED was significantly associated with higher favorable outcomes compared to PED (odds ratio: 0.37; confidence interval: 0.17 to 0.81; p = 0.01).
This study showed that both PED and FRED had comparable rates of complete occlusion, retreatment and complications, and FRED also demonstrated a higher likelihood of achieving favorable outcomes. The study underscores the need for further research with larger cohorts and longer follow up to consolidate these findings.
血流导向技术的进步彻底改变了颅内动脉瘤的治疗方式。管道栓塞装置(PED)和血流导向腔内装置(FRED)已成为该领域的重要工具。本研究旨在比较PED和FRED治疗颅内动脉瘤的安全性和有效性。
按照系统评价和Meta分析的首选报告项目(PRISMA)指南,在PubMed、科学网和Scopus数据库中进行了全面的文献检索。纳入比较PED和FRED的研究,数据提取集中在研究特征、患者人口统计学以及临床和影像学结果。主要结局为良好结局,定义为改良Rankin量表(mRS)0 - 2分以及完全/近完全闭塞,次要结局包括再治疗率以及血栓栓塞和出血并发症。
纳入了五项研究,共1238例患者。在6个月和1年时的完全闭塞、末次随访时的完全/近完全闭塞、再治疗率以及血栓栓塞、支架内血栓形成和出血并发症方面,PED和FRED之间未发现显著差异。然而,与PED相比,FRED与更高的良好结局显著相关(优势比:0.37;置信区间:0.17至0.81;p = 0.01)。
本研究表明,PED和FRED的完全闭塞率、再治疗率和并发症发生率相当,并且FRED实现良好结局的可能性也更高。该研究强调需要进行更大样本量队列和更长随访时间的进一步研究,以巩固这些发现。